ALC - Alcon Inc.
NYSE
->
Healthcare
->
Medical Instruments & Supplies
Geneva,
Switzerland
Type: Equity
ALC price evolution
ALC
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $1768 | $2123 | $2104 | $2083 |
| Inventory | $2378 | $2332 | $2319 | $2322 |
| Total current assets | $6319 | $5987 | $5704 | $5647 |
| Long term investments | ||||
| Property, plant & equipment | $4842 | $4686 | $4682 | $4723 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $30362 | $29718 | $29565 | $29614 |
| Current liabilities | ||||
| Accounts payable | $849 | $868 | $818 | $811 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $2456 | $2340 | $2271 | $2480 |
| Long term debt | $4933 | $4882 | $4881 | $4929 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $8973 | $8777 | $8738 | $8990 |
| Shareholders' equity | ||||
| Retained earnings | $21295 | $20991 | $20864 | $20624 |
| Other shareholder equity | $38 | -$43 | -$26 | $12 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $270 | $1575 | $1557 | |
| Short term investments | $242 | $3 | ||
| Net receivables | $2083 | $1964 | $1786 | $1649 |
| Inventory | $2322 | $2109 | $1899 | $1644 |
| Total current assets | $5647 | $5193 | $5386 | $4987 |
| Long term investments | $23967 | $52 | $40 | |
| Property, plant & equipment | $4723 | $4416 | $4083 | $3783 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $22613 | |||
| Total investments | ||||
| Total assets | $29614 | $29209 | $27999 | $27600 |
| Current liabilities | ||||
| Accounts payable | $811 | $861 | $903 | $876 |
| Deferred revenue | ||||
| Short long term debt | $216 | $91 | $108 | |
| Total current liabilities | $2480 | $2782 | $2472 | $2258 |
| Long term debt | $4929 | $4900 | $3966 | $3949 |
| Total noncurrent liabilities | $6520 | |||
| Total debt | ||||
| Total liabilities | $8990 | $9532 | $8743 | $8778 |
| Shareholders' equity | ||||
| Retained earnings | $20624 | $19673 | $19356 | $18899 |
| Other shareholder equity | $12 | $17 | $19236 | $18802 |
| Total shareholder equity | $20624 | $19256 | $18822 | |
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2454 | $2459 | ||
| Cost of revenue | ||||
| Gross Profit | $1371 | $1385 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1035 | $1014 | ||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $29 | $87 | ||
| Interest expense | -$50 | -$45 | ||
| Net income | ||||
| Net income | $263 | $248 | ||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9455 | $8717 | $6833 | |
| Cost of revenue | $3777 | |||
| Gross Profit | $5254 | $4809 | $3056 | |
| Operating activities | ||||
| Research & development | $672 | |||
| Selling, general & administrative | $2672 | |||
| Total operating expenses | $4073 | $4076 | $7099 | |
| Operating income | -$266 | |||
| Income from continuing operations | ||||
| EBIT | -$266 | |||
| Income tax expense | -$142 | $128 | -$104 | |
| Interest expense | -$183 | -$176 | -$124 | |
| Net income | ||||
| Net income | $974 | $335 | -$531 | |
| Income (for common shares) | -$531 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$834 | -$351 | -$218 | -$1094 |
| Financing activities | ||||
| Dividends paid | -$130 | -$130 | -$116 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$318 | -$237 | -$66 | -$211 |
| Effect of exchange rate | $6 | -$5 | -$10 | $31 |
| Change in cash and equivalents | $472 | $278 | $47 | $114 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | $376 | -$531 | ||
| Operating activities | ||||
| Depreciation | $1217 | $1615 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | $1345 | $823 | ||
| Investing activities | ||||
| Capital expenditures | -$700 | -$479 | ||
| Investments | -$18 | -$11 | ||
| Total cash flows from investing | -$1094 | -$1865 | -$1198 | -$572 |
| Financing activities | ||||
| Dividends paid | -$116 | -$100 | -$54 | |
| Sale and purchase of stock | ||||
| Net borrowings | -$63 | $536 | ||
| Total cash flows from financing | -$211 | -$8 | -$123 | $466 |
| Effect of exchange rate | $31 | $61 | -$6 | $18 |
| Change in cash and equivalents | $114 | -$595 | $18 | $735 |
News
|
Reasons to Retain Alcon Stock in Your Portfolio for Now
Zacks · via Yahoo Finance
13 Dec 2024
|
|
Why Alcon (ALC) is a Top Growth Stock for the Long-Term
Zacks · via Yahoo Finance
6 Dec 2024
|
|
Alcon Inc. (ALC): A Bull Case Theory
Insider Monkey · via Yahoo Finance
3 Dec 2024
|
|
Alcon Inc. (ALC): Among UBS’ Top Tech Based Disruptive Stocks For 2030
Insider Monkey · via Yahoo Finance
30 Oct 2024
|
|
Alcon Inc. (ALC): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
Insider Monkey · via Yahoo Finance
21 Aug 2024
|
|
Why Alcon (ALC) Might Surprise This Earnings Season
Zacks via Yahoo Finance
10 May 2024
|
|
Soft Instrument Orders Likely to Hurt PacBio's (PACB) Q1 Earnings
Zacks via Yahoo Finance
7 May 2024
|
|
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Zacks via Yahoo Finance
6 May 2024
|
|
Here's How Cresco Labs (CRLBF) is Placed Before Q1 Earnings
Zacks via Yahoo Finance
6 May 2024
|
|
Should SNDL (SNDL) be in Your Portfolio Ahead of Q1 Earnings?
Zacks via Yahoo Finance
6 May 2024
|
Fundamentals
| Market cap | $41.91B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 494.50M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.44 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.57 |
| Quick ratio | 1.60 |